Broncus Holding Corporation (HKG:2216)
Hong Kong · Delayed Price · Currency is HKD 2.280
-0.020 (-0.87%)
At close: Jan 21, 2026
Broncus Holding Revenue
Broncus Holding had revenue of $1.65M USD in the half year ending June 30, 2025, a decrease of -68.44%. This brings the company's revenue in the last twelve months to $6.08M, down -30.33% year-over-year. In the year 2024, Broncus Holding had annual revenue of $8.13M, down -20.71%.
Revenue (ttm)
$6.08M
Revenue Growth
-30.33%
P/S Ratio
25.16
Revenue / Employee
$30.40K
Employees
200
Market Cap
1.20B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.13M | -2.12M | -20.71% |
| Dec 31, 2023 | 10.26M | 842.00K | 8.95% |
| Dec 31, 2022 | 9.41M | -1.48M | -13.57% |
| Dec 31, 2021 | 10.89M | 7.63M | 234.18% |
| Dec 31, 2020 | 3.26M | -4.81M | -59.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |